Prostate Cell News Volume 9.37 | Sep 28 2018

TOP STORY

ZFX Mediates Non-Canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer

The authors showed that independent of ligand, androgen receptor splice variant 7 (AR-V7) binds both androgen-responsive elements (AREs) and non-canonical sites distinct from full-length AR (AR-FL) targets. Consequently, AR-V7 not only recapitulated AR-FL’s partial functions but also regulated an additional gene expression program uniquely via binding to gene promoters rather than ARE enhancers. [Mol Cell] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis

Loss of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) in vivo or in human prostate cancer cells reduced the expression of two key lipogenic enzymes, acetyl-CoA carboxylase and fatty acid synthase. This reduction was mediated via a post-transcriptional mechanism, potentially involving a decrease in protein translation. [Cancer Res] Abstract

ASPM Promotes Prostate Cancer Stemness and Progression by Augmenting Wnt-Dvl-3-β-Catenin Signaling

Investigators reported that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintained the prostate cancer stem cell (CSC) subpopulation by augmenting the Wnt-β-catenin signaling in prostate cancer (PCA). ASPM expression was incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. [Oncogene] Abstract

Targeting the Androgen Receptor (AR) with AR Degradation Enhancer ASC-J9 Led to Increase Docetaxel Sensitivity via Suppressing the p21 Expression

The authors found docetaxel may have adverse effect of increasing AR protein stability via suppressing AR ubiquitination due to increased AR phosphorylation. They also demonstrated that targeting AR with ASC-J9 led to suppressing the AR-increased p21 expression to improve the docetaxel sensitivity in the CRPC cells that already developed docetaxel resistance. [Cancer Lett] Abstract

Targeting the BRD4-HOXB13 Co-Regulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer

Scientists uncovered that castration resistant prostate cancers (CRPCs) relied on BRD4-HOXB13 epigenetic reprogramming for androgen-independent cell proliferation. BRD4, a member of the BET bromodomain family epigenetically promoted HOXB13 expression. [Mol Cancer Ther] Abstract

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

IL6 significantly increased androgen-dependent AR activity in LNCaP cells but did not influence AR activity at castrate androgen levels. Biochemical inhibition of STAT3 with the small molecule inhibitor galiellalactone significantly reduced AR activity in several prostate- and breast-cancer cell lines. [Mol Cancer Ther] Abstract

Kinase PIM1 Promotes Prostate Cancer Cell Growth via c-Myc-RPS7-Driven Ribosomal Stress

PIM1 was found to be a component of the small 40S ribosomal subunit, and could regulate the expression of RPS7. Researchers also revealed that PIM1 enhanced the protein stability of c-Myc. In addition, PIM1 was found to be a component of the small 40S ribosomal subunit, and could regulate the expression of RPS7. [Carcinogenesis] Abstract

SMC1A Is Associated with Radioresistance in Prostate Cancer and Acts by Regulating Epithelial-Mesenchymal Transition and Cancer Stem-Like Properties

Investigators describe functional studies that were performed to investigate the role of structural maintenance of chromosome-1 (SMC1A) in radioresistance of metastatic prostate cancer cells. Short hairpin RNA was used to suppress SMC1A in metastatic castration-resistant prostate cancer cells, DU145 and PC3. [Mol Carcinog] Abstract

Mesenchymal Stem Cells Recruited by Castration-Induced Inflammation Activation Accelerate Prostate Cancer Hormone Resistance via Chemokine Ligand 5 Secretion

Androgen deprivation (AD)-induced oxidative stress could promote the inflammatory response mediated by IL-1β secretion via activating the NF-κB signaling pathway. N-acetylcysteine could significantly inhibit MSC recruitment to prostate cancer sites when AD was performed. [Stem Cell Res Ther] Full Article

Paclitaxel Resistance and the Role of miRNAs in Prostate Cancer Cell Lines

Expression study of 86 miRNAs by RT-PCR demonstrated that several of the miRNAs were expressed at different levels in paclitaxel-resistant cells compared to wild-type cells. The expression profiles of these miRNAs varied among different prostate cancer cell line types, with 13 miRNAs being up-regulated in the resistant cells. [World J Urol] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer

The authors discuss about the importance of targeting Nrf-2-antioxidant signaling, NF-κB inflammatory response and androgen receptor (AR) signaling in prostate cancer (PCa). They discuss the crosstalk between these three critical pathways as well as how the anti-inflammatory antioxidant phytochemicals like sulforaphane and curcumin, which can also target AR, can be ideal candidates in the chemoprevention of PCa. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

OncBioMune Initiates Phase II Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer

OncBioMune Pharmaceuticals, Inc. provided a status update on the Phase II clinical trial of ProscaVax for early-stage prostate cancer. [OncBioMune Pharmaceuticals Inc. (GlobeNewswire, Inc.)] Press Release

LSU Health New Orleans Leads U.S. Recruitment for Advanced Prostate Cancer Clinical Trial

LSU Health New Orleans Scott Cancer Center has enrolled the first patients in the United States in a National Cancer Institute/Southwest Oncology Group clinical trial for men whose prostate cancer has spread. [LSU Health Sciences Center New Orleans] Press Release

Astellas Receives Positive CHMP Opinion for XTANDI^™ (Enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. announced that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to expand the indication for Xtandi to include adult men with high-risk non-metastatic castration-resistant prostate cancer. [Astellas Pharma Inc.] Press Release

CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models

Crown Bioscience announced the addition of unique, well characterized, fully annotated PDX models of prostate cancer. [Crown Bioscience Inc.] Press Release

Finland joins Europe’s Bold Open-Access Push

Finland’s national research funder has signed up to Plan S — a push by a group of European organizations to make a radical change to the way that research results are published. [Nature News] Editorial

Biologists Irate at NSF’s New One-Proposal Cap

The National Science Foundation (NSF) in Alexandria, Virginia, has made several tweaks to its grant proposal policies in recent years to keep staff and reviewers from being overwhelmed by the rising number of submissions. But some biologists say the latest change goes too far. [ScienceInsider] Editorial

Hundreds of Academics at Top UK Universities Accused of Bullying

Hundreds of academics have been accused of bullying students and colleagues in the past five years, prompting concerns that a culture of harassment and intimidation is thriving in Britain’s leading universities. [The Guardian] Editorial

NEW Cell Symposia: Single Cells: Technology to Biology
February 24-26, 2019
Singapore, Singapore

Visit our events page to see a complete list of events in the community.

NEW Assistant/Associate/Professor – Department of Cancer Biology (University of Cincinnati College of Medicine)

Postdoctoral Fellows – Prostate Cancer Research (Weill Cornell Medicine)

Postdoctoral Position – Genitourinary Cancers (Columbia University Medical Center)

Assistant Professor – Basic and Translational Cancer Research (Texas Tech University Health Sciences Center)

Assistant/Associate Faculty Position – Prostate Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Prostate Cancer Progression (Aarhus University)

Postdoctoral Position – Translational Cancer Research (University of California, Davis)

Postdoctoral Fellow/Research Scientist – Prostate Cancer (Università della Svizzera italiana)

Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic)

Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.